TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)

Inclusion Criteria: * Fasting LDL-C levels \>2.5 mmol/L and \<4.5 mmol/L, HDL-C levels \<1.8 mmol/L and \>0.8 mmol/L, and TG levels \<4.5 mmol/L after run in or washout of existing therapies * Not on lipid-altering therapy at screening or on lipid-altering treatment regimens at screening Exclusion Criteria: * Body mass index \>32 kg/m2; * Participation in another clinical study involving an investigational or marketed drug within 30 days prior to enrolment (Visit 2); * Any clinical manifestation of atherosclerotic vascular disease; * Diagnosis of type 1 diabetes; * Uncontrolled type 2 diabetes: haemoglobin A1c \>8%; * Uncontrolled hypertension: sitting systolic blood pressure \>160 mmHg and/or sitting diastolic blood pressure \>90 mmHg; * History of hyperaldosteronism; * Active muscle disease or persistent creatine kinase concentration \>3 × the upper limit of normal (ULN). One retest will be allowed after 1 week to verify the result;